Evidence map›Paper›PMID 22155308›Full record

ArticleBiochemical pharmacology2012

Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone.

Krisztina M Papp-Wallace, Christopher R Bethel, Thomas D Gootz, Wenchi Shang, Justin Stroh, William Lau, Dale McLeod, Loren Price, Anthony Marfat, Anne Distler and 7 more

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Krisztina M Papp-WallaceResearch Service, Louis Stokes Cleveland Department of Veteran Affairs Medical Center, Cleveland, OH 44106, USA.
Christopher R Bethel
Thomas D Gootz
Wenchi Shang
Justin Stroh
William Lau
Dale McLeod
Loren Price
Anthony Marfat
Anne Distler
Sarah M Drawz
Hansong Chen
Emily Harry
Micheal Nottingham
Paul R Carey
John D Buynak
Robert A Bonomo
Pfizer (United States) · USSouthern Methodist University · USLouis Stokes Cleveland VA Medical Center · USCase Western Reserve University · USCuyahoga Community College · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
RAMAN STUDIES OF ENZYME COMPLEXES IN SOLUTION &CRYSTALSR01GM054072 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI CAREY, PAUL R · 1996 to 2013
$3.5M
NIAID NIH HHS R01 AI063517NIGMS NIH HHS R01 GM054072NIGMS NIH HHS R01 GM54072NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

β-Lactamase inhibitors (clavulanic acid, sulbactam, and tazobactam) contribute significantly to the longevity of the β-lactam antibiotics used to treat serious infections. In the quest to design more potent compounds and to understand the mechanism of action of known inhibitors, 6β-(hydroxymethyl)penicillanic acid sulfone (6β-HM-sulfone) was tested against isolates expressing the class A TEM-1 β-lactamase and a clinically important variant of the AmpC cephalosporinase of Pseudomonas aeruginosa, PDC-3. The addition of the 6β-HM-sulfone inhibitor to ampicillin was highly effective. 6β-HM-sulfone inhibited TEM-1 with an IC(50) of 12 ± 2 nM and PDC-3 with an IC(50) of 180 ± 36 nM, and displayed lower partition ratios than commercial inhibitors, with partition ratios (k(cat)/k(inact)) equal to 174 for TEM-1 and 4 for PDC-3. Measured for 20 h, 6β-HM-sulfone demonstrated rapid, first-order inactivation kinetics with the extent of inactivation being related to the concentration of inhibitor for both TEM-1 and PDC-3. Using mass spectrometry to gain insight into the intermediates of inactivation of this inhibitor, 6β-HM-sulfone was found to form a major adduct of +247 ± 5 Da with TEM-1 and +245 ± 5 Da with PDC-3, suggesting that the covalently bound, hydrolytically stabilized acyl-enzyme has lost a molecule of water (HOH). Minor adducts of +88 ± 5 Da with TEM-1 and +85 ± 5 Da with PDC-3 revealed that fragmentation of the covalent adduct can result but appeared to occur slowly with both enzymes. 6β-HM-sulfone is an effective and versatile β-lactamase inhibitor of representative class A and C enzymes.

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-LactamasesCatalytic DomainComputer SimulationEscherichia coliModels, MolecularMolecular StructureProtein ConformationPseudomonas aeruginosaSulbactam6beta-(hydroxymethyl)penicillanic acid sulfoneAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-lactamase TEM-1Sulbactam

Identifiers

PMID22155308
PMCPMC3319978
OpenAlexW2044400914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.